Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Effects on Norepinephrine in Septic Shock
NCT02638545Phase 3Completed
- Sponsor
- Sapienza University of Rome
- Start
- Sep 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dexmedetomidine in septic shock, sponsored by Sapienza University of Rome. Primary endpoint: Norepinephrine dose at 4 hours. Started Sep 2015; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT02638545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638545.